Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market to Register Substantial Expansion by 2024

Vesicular monoamine transporter 2 (VMAT2) is a membrane-embedded protein that is responsible for uptake of monoamines neurotransmitters such as dopamine, serotonin, norepinephrine, and histamines into the synaptic vesicles in monoaminergic neurons. Vesicular monoamine transporter proteins 2 are expressed in the central nervous system (CNS) and plays the crucial role in the signaling process between the monoamine neurons. VMAT2 is the only transporter that carries the cytoplasmic dopamine into the vesicles. Hence, it is widely targeted for therapeutic treatments of Parkinson’s and Huntington’s disease. VMAT2 inhibitors block VMAT2 proteins and control the neurotransmission activity, thereby reducing the unwanted body movements caused by Huntington’s disease and tardive dyskinesia.
VMAT2 inhibitors are widely used for the treatment of uncontrollable involuntary, repetitive body movements caused due to tardive dyskinesia and Huntington’s disease.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37724

The global vesicular monoamine transporter-2 inhibitors market is driven primarily by rise in incidence of the diseases mentioned above. Huntington’s disease is a progressive brain disorder that causes involuntary body movement, loss of recognition ability, and emotional problems. Prevalence of this disease is high in the developed countries, especially in Europe. An estimated five to seven people per 100,000 are affected by Huntington’s disease in countries in the West. High prevalence of Huntington’s disease has been observed in Venezuela, where around 700 people per 100,000 have the disease. Tardive dyskinesia is a side effect of antipsychotic medications used for the treatment of schizophrenia and other mental health disorders. In the U.S., this disease occurs in 15% to 30% patients who have received long-term neuroleptic medication. Moreover, the investigational studies for the discovery of novel therapeutics using VMAT2 inhibitor to treat methamphetamine abuse are likely to boost demand during the forecast period. However, side effects of VMAT 2 inhibitors such as sleepiness, dry mouth, constipation, and heart conduction changes are likely to hamper the growth of the VMAT2 inhibitors market.

Request for Analysis of COVID19 Impact on Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=37724

The global VMAT2 inhibitors market can be segmented based on application and region. In terms of application, the global market can categorized into Huntington’s disease and tardive dyskinesia. The tardive dyskinesia segment is projected to account for high market share by 2025. The segment is anticipated to record exponential growth rate during the forecast period. People with schizophrenia, bipolar disorders, and other neuropsychiatric disorders undergoing long-term medical treatments with antipsychotic medication are more likely to develop symptoms of tardive dyskinesia.

Pre-Book Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=37724<ype=S

Geographically, the global VMAT2 inhibitors market can be segmented into four major regions: North America, Europe, Asia Pacific, and Rest of the World. North America is expected to hold significant share of the global market by 2025. Large market share of the region is attributed to increase in number of patients with bipolar diseases, schizophrenia, and Huntington’s disease in this region. Europe is likely to record high CAGR during the forecast period. High prevalence of Huntington’s disease and rise in incidence of tardive dyskinesia are projected to drive the market in the region during the forecast period. The market in Asia Pacific is anticipated to expand at a moderate growth rate during the forecast period.

Key players operating in the global VMAT2 inhibitors market include Tocris Bioscience, Neurocrine Biosciences, Inc., Teva Pharmaceuticals Industries Ltd., EUSA Pharma (UK) Limited, and Lundbeck, Inc.

Read More Reports: https://www.prnewswire.com/news-releases/growing-need-to-effectively-manage-increasing-burden-of-diabetes-to-propel-diabetes-devices-market-forward-tmr-301097980.html

Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.